Given the acknowledgment that immune checkpoint blockade (ICB) cancer immunotherapy in accordance with the inhibition of key immune checkpoints, we assessed some representative molecules and discovered that PD-1, PD-L1, and CTLA4 were significantly increasingly expressed in the C1 group (Figure 6A). Here, PDCD1 is linked to cancer.